Cargando…
Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study
Atopic dermatitis (AD) is a chronic, itchy skin condition that affects 15–20% of children but may occur at any age. It is estimated that 16.5 million US adults (7.3%) have AD that initially began at age >2 years, with nearly 40% affected by moderate or severe disease. Therefore, a quantitative me...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382656/ https://www.ncbi.nlm.nih.gov/pubmed/35990535 http://dx.doi.org/10.1016/j.xjidi.2022.100107 |
_version_ | 1784769331200000000 |
---|---|
author | Medela, Alfonso Mac Carthy, Taig Aguilar Robles, S. Andy Chiesa-Estomba, Carlos M. Grimalt, Ramon |
author_facet | Medela, Alfonso Mac Carthy, Taig Aguilar Robles, S. Andy Chiesa-Estomba, Carlos M. Grimalt, Ramon |
author_sort | Medela, Alfonso |
collection | PubMed |
description | Atopic dermatitis (AD) is a chronic, itchy skin condition that affects 15–20% of children but may occur at any age. It is estimated that 16.5 million US adults (7.3%) have AD that initially began at age >2 years, with nearly 40% affected by moderate or severe disease. Therefore, a quantitative measurement that tracks the evolution of AD severity could be extremely useful in assessing patient evolution and therapeutic efficacy. Currently, SCOring Atopic Dermatitis (SCORAD) is the most frequently used measurement tool in clinical practice. However, SCORAD has the following disadvantages: (i) time consuming—calculating SCORAD usually takes about 7–10 minutes per patient, which poses a heavy burden on dermatologists and (ii) inconsistency—owing to the complexity of SCORAD calculation, even well-trained dermatologists could give different scores for the same case. In this study, we introduce the Automatic SCORAD, an automatic version of the SCORAD that deploys state-of-the-art convolutional neural networks that measure AD severity by analyzing skin lesion images. Overall, we have shown that Automatic SCORAD may prove to be a rapid and objective alternative method for the automatic assessment of AD, achieving results comparable with those of human expert assessment while reducing interobserver variability. |
format | Online Article Text |
id | pubmed-9382656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93826562022-08-18 Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study Medela, Alfonso Mac Carthy, Taig Aguilar Robles, S. Andy Chiesa-Estomba, Carlos M. Grimalt, Ramon JID Innov Methods & New Technology Atopic dermatitis (AD) is a chronic, itchy skin condition that affects 15–20% of children but may occur at any age. It is estimated that 16.5 million US adults (7.3%) have AD that initially began at age >2 years, with nearly 40% affected by moderate or severe disease. Therefore, a quantitative measurement that tracks the evolution of AD severity could be extremely useful in assessing patient evolution and therapeutic efficacy. Currently, SCOring Atopic Dermatitis (SCORAD) is the most frequently used measurement tool in clinical practice. However, SCORAD has the following disadvantages: (i) time consuming—calculating SCORAD usually takes about 7–10 minutes per patient, which poses a heavy burden on dermatologists and (ii) inconsistency—owing to the complexity of SCORAD calculation, even well-trained dermatologists could give different scores for the same case. In this study, we introduce the Automatic SCORAD, an automatic version of the SCORAD that deploys state-of-the-art convolutional neural networks that measure AD severity by analyzing skin lesion images. Overall, we have shown that Automatic SCORAD may prove to be a rapid and objective alternative method for the automatic assessment of AD, achieving results comparable with those of human expert assessment while reducing interobserver variability. Elsevier 2022-02-11 /pmc/articles/PMC9382656/ /pubmed/35990535 http://dx.doi.org/10.1016/j.xjidi.2022.100107 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Methods & New Technology Medela, Alfonso Mac Carthy, Taig Aguilar Robles, S. Andy Chiesa-Estomba, Carlos M. Grimalt, Ramon Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study |
title | Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study |
title_full | Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study |
title_fullStr | Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study |
title_full_unstemmed | Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study |
title_short | Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study |
title_sort | automatic scoring of atopic dermatitis using deep learning: a pilot study |
topic | Methods & New Technology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382656/ https://www.ncbi.nlm.nih.gov/pubmed/35990535 http://dx.doi.org/10.1016/j.xjidi.2022.100107 |
work_keys_str_mv | AT medelaalfonso automaticscoringofatopicdermatitisusingdeeplearningapilotstudy AT maccarthytaig automaticscoringofatopicdermatitisusingdeeplearningapilotstudy AT aguilarroblessandy automaticscoringofatopicdermatitisusingdeeplearningapilotstudy AT chiesaestombacarlosm automaticscoringofatopicdermatitisusingdeeplearningapilotstudy AT grimaltramon automaticscoringofatopicdermatitisusingdeeplearningapilotstudy |